168 related articles for article (PubMed ID: 17848574)
21. The p53 mRNA-Mdm2 interaction.
Naski N; Gajjar M; Bourougaa K; Malbert-Colas L; Fåhraeus R; Candeias MM
Cell Cycle; 2009 Jan; 8(1):31-4. PubMed ID: 19106616
[TBL] [Abstract][Full Text] [Related]
22. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
[TBL] [Abstract][Full Text] [Related]
23. p53 ubiquitination: Mdm2 and beyond.
Brooks CL; Gu W
Mol Cell; 2006 Feb; 21(3):307-15. PubMed ID: 16455486
[TBL] [Abstract][Full Text] [Related]
24. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
[TBL] [Abstract][Full Text] [Related]
25. Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover.
Dias SS; Hogan C; Ochocka AM; Meek DW
FEBS Lett; 2009 Nov; 583(22):3543-8. PubMed ID: 19833129
[TBL] [Abstract][Full Text] [Related]
26. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
[TBL] [Abstract][Full Text] [Related]
27. E2F1 inhibits MDM2 expression in a p53-dependent manner.
Tian X; Chen Y; Hu W; Wu M
Cell Signal; 2011 Jan; 23(1):193-200. PubMed ID: 20837136
[TBL] [Abstract][Full Text] [Related]
28. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
[TBL] [Abstract][Full Text] [Related]
29. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy.
Müller P; Ceskova P; Vojtesek B
J Biol Chem; 2005 Feb; 280(8):6682-91. PubMed ID: 15613472
[TBL] [Abstract][Full Text] [Related]
30. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
31. A single synonymous mutation determines the phosphorylation and stability of the nascent protein.
Karakostis K; Vadivel Gnanasundram S; López I; Thermou A; Wang L; Nylander K; Olivares-Illana V; Fåhraeus R
J Mol Cell Biol; 2019 Mar; 11(3):187-199. PubMed ID: 30252118
[TBL] [Abstract][Full Text] [Related]
32. Protein phosphatase 1 nuclear targeting subunit is a hypoxia inducible gene: its role in post-translational modification of p53 and MDM2.
Lee SJ; Lim CJ; Min JK; Lee JK; Kim YM; Lee JY; Won MH; Kwon YG
Cell Death Differ; 2007 Jun; 14(6):1106-16. PubMed ID: 17318220
[TBL] [Abstract][Full Text] [Related]
33. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.
Meulmeester E; Pereg Y; Shiloh Y; Jochemsen AG
Cell Cycle; 2005 Sep; 4(9):1166-70. PubMed ID: 16082221
[TBL] [Abstract][Full Text] [Related]
34. Long lasting inhibition of Mdm2-p53 interaction potentiates mesenchymal stem cell differentiation into osteoblasts.
Daniele S; Giacomelli C; Pietrobono D; Barresi E; Piccarducci R; La Pietra V; Taliani S; Da Settimo F; Marinelli L; Novellino E; Martini C; Trincavelli ML
Biochim Biophys Acta Mol Cell Res; 2019 May; 1866(5):737-749. PubMed ID: 30703414
[TBL] [Abstract][Full Text] [Related]
35. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.
Ma J; Martin JD; Zhang H; Auger KR; Ho TF; Kirkpatrick RB; Grooms MH; Johanson KO; Tummino PJ; Copeland RA; Lai Z
Biochemistry; 2006 Aug; 45(30):9238-45. PubMed ID: 16866370
[TBL] [Abstract][Full Text] [Related]
36. Hsp90β interacts with MDM2 to suppress p53-dependent senescence during skeletal muscle regeneration.
He MY; Xu SB; Qu ZH; Guo YM; Liu XC; Cong XX; Wang JF; Low BC; Li L; Wu Q; Lin P; Yan SG; Bao Z; Zhou YT; Zheng LL
Aging Cell; 2019 Oct; 18(5):e13003. PubMed ID: 31313490
[TBL] [Abstract][Full Text] [Related]
37. Chaperone-dependent stabilization and degradation of p53 mutants.
Muller P; Hrstka R; Coomber D; Lane DP; Vojtesek B
Oncogene; 2008 May; 27(24):3371-83. PubMed ID: 18223694
[TBL] [Abstract][Full Text] [Related]
38. The regulation of MDM2 oncogene and its impact on human cancers.
Zhao Y; Yu H; Hu W
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):180-9. PubMed ID: 24389645
[TBL] [Abstract][Full Text] [Related]
39. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
40. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
Moumen A; Masterson P; O'Connor MJ; Jackson SP
Cell; 2005 Dec; 123(6):1065-78. PubMed ID: 16360036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
